Evotec SE announced on November 19, 2026, that its strategic protein degradation partnership with Bristol Myers Squibb has received a second Investigational New Drug acceptance from the U.S. Food and Drug Administration for a cereblon E3 ligase modulator candidate.
Key Highlights
- Second IND accepted: The FDA accepted a second investigational drug candidate from the Evotec-Bristol Myers Squibb molecular glue partnership.
- Candidate type: The newly accepted candidate is a cereblon E3 ligase modulator (CELMoD), according to the filing.
- Phase 1 timeline: The second candidate is expected to enter a Phase 1 clinical trial in 2027.
- First candidate already in trial: The first partnership candidate entered a Phase 1 clinical trial in advanced clear cell renal cell carcinoma in March 2026.
- Partnership origin: The collaboration was initiated in 2018 with Celgene, now Bristol Myers Squibb, and was expanded in 2022.
- Exchange listing: Evotec SE trades on NASDAQ:EVO and on the Frankfurt Prime Standard under the symbol EVT.
Evotec and Bristol Myers Squibb Advance Second Molecular Glue Candidate to IND Stage
Evotec SE disclosed that its long-running molecular glue discovery collaboration with Bristol Myers Squibb has achieved a second FDA IND acceptance. The partnership, which began in 2018 with Celgene before that company became part of Bristol Myers Squibb, was expanded in 2022 and focuses on discovering and developing molecular glue degraders for oncology and other therapeutic areas. The second accepted candidate is a CELMoD and is expected to advance into a Phase 1 clinical trial in 2027, according to the announcement.
The filing notes that the first candidate generated under the partnership entered a Phase 1 clinical trial in advanced clear cell renal cell carcinoma in March 2026. According to the company, the collaboration combines Evotec's high-performance multi-omics screening, AI-supported data analytics, and drug design capabilities with Bristol Myers Squibb's CELMoD agent library. Evotec's Chief Scientific Officer, Dr. Joanna Holbrook, stated in the announcement: "The progression of a second molecular glue candidate to IND acceptance demonstrates the repeatability and productivity of our discovery platform."
The filing describes molecular glue degraders as compounds that induce interactions between an E3 ubiquitin ligase and a molecular target, leading to ubiquitination and subsequent degradation of the recruited protein. Evotec noted that CELMoDs "enable pharmacological modulation of proteins that may not be amenable to traditional inhibitor or agonist approaches, thereby expanding the potentially druggable proteome." The announcement also contains forward-looking statements, which the company identifies as such and states are subject to known and unknown risks and uncertainties, with no assurance that expectations will prove correct.
What Was Disclosed
Evotec SE announced FDA acceptance of a second IND for a CELMoD candidate from its molecular glue partnership with Bristol Myers Squibb. The candidate is expected to enter Phase 1 in 2027, while the first partnership candidate began Phase 1 in March 2026.



Please wait processing your request...